Literature DB >> 18090718

Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders?

Jonathan H McKinnon1, Bart M Demaerschalk, John N Caviness, Kay E Wellik, Charles H Adler, Dean M Wingerchuk.   

Abstract

BACKGROUND: : Akinetic-rigid syndromes are a heterogeneous group of diseases with overlapping clinical manifestations. A recent American Academy of Neurology practice parameter indicated that olfactory testing was "probably useful" for differentiating idiopathic Parkinson disease (IPD) from other diseases with features of parkinsonism.
OBJECTIVE: : To determine the diagnostic accuracy of olfactory testing for differentiating IPD from other parkinsonian disorders.
METHODS: : The objective was addressed using a structured, evidence-based, critically appraised topic format. This format includes development of a clinical scenario, focused and answerable clinical question, search strategy, evidence appraisal, reporting and interpretation of results, commentary, and bottom line conclusions. Participants included neurology consultants and residents, clinical epidemiologists, a medical librarian, and neurologists with expertise in movement disorders.
RESULTS: : Two studies evaluated the diagnostic accuracy of olfactory testing within a broad spectrum of parkinsonian syndromes. Each study examined different test methods [University of Pennsylvania Smell Identification Test; "Sniffin' Sticks"] and both were compromised by several potential biases in sampling and outcome evaluation. The University of Pennsylvania Smell Identification Test is moderately sensitive (77%; likelihood ratio 0.27) and specific (85%; likelihood ratio 4.9) for differentiation of IPD from non-IPD syndromes, but less specific (62%; likelihood ratio 2.0) for distinguishing IPD from multiple system atrophy.
CONCLUSION: : The diagnostic accuracy of olfactory testing for differentiating IPD from other disorders is insufficient to justify its routine clinical use but available evidence is derived from small samples and studies of questionable validity. Recommendations for future research of olfactory testing for diagnosis and disease predication are discussed.

Entities:  

Mesh:

Year:  2007        PMID: 18090718     DOI: 10.1097/NRL.0b013e31815a351a

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  12 in total

Review 1.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.

Authors:  Min Shi; Joshua Bradner; Aneeka M Hancock; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Un Jung Kang; Kevin C Cain; Yu Wang; Jan Aasly; David Goldstein; Jing Zhang
Journal:  Ann Neurol       Date:  2011-03-11       Impact factor: 10.422

3.  Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders.

Authors:  Thomas G Beach; Charles L White; Christa L Hladik; Marwan N Sabbagh; Donald J Connor; Holly A Shill; Lucia I Sue; Jeanne Sasse; Jyothi Bachalakuri; Jonette Henry-Watson; Haru Akiyama; Charles H Adler
Journal:  Acta Neuropathol       Date:  2008-11-04       Impact factor: 17.088

4.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction.

Authors:  Thomas G Beach; Charles H Adler; LihFen Lue; Lucia I Sue; Jyothi Bachalakuri; Jonette Henry-Watson; Jeanne Sasse; Sarah Boyer; Scophil Shirohi; Reed Brooks; Jennifer Eschbacher; Charles L White; Haru Akiyama; John Caviness; Holly A Shill; Donald J Connor; Marwan N Sabbagh; Douglas G Walker
Journal:  Acta Neuropathol       Date:  2009-04-28       Impact factor: 17.088

Review 5.  Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.

Authors:  Ilan Halperin; Micaela Morelli; Amos D Korczyn; Moussa B H Youdim; Silvia A Mandel
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

6.  Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy.

Authors:  Silvia A Mandel; Micaela Morelli; Ilan Halperin; Amos D Korczyn
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

7.  Olfactory loss in Parkinson's disease.

Authors:  Antje Haehner; Thomas Hummel; Heinz Reichmann
Journal:  Parkinsons Dis       Date:  2011-04-21

Review 8.  Many Faces of Parkinson's Disease: Non-Motor Symptoms of Parkinson's Disease.

Authors:  Hye Mi Lee; Seong-Beom Koh
Journal:  J Mov Disord       Date:  2015-05-31

9.  Olfactory dysfunction in persian patients suffering from parkinson's disease.

Authors:  Akbar Soltanzadeh; Mehdi Shams; Hamid Noorolahi; Askar Ghorbani; Farzad Fatehi
Journal:  Iran J Neurol       Date:  2011

10.  Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients.

Authors:  Angela E P Bouwmans; Annemarie M M Vlaar; Werner H Mess; Alfons Kessels; Wim E J Weber
Journal:  BMJ Open       Date:  2013-04-02       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.